Published in Kidney Int on April 01, 2001
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet (2013) 7.03
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol (2010) 3.01
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol (2009) 2.03
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol (2009) 1.62
Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol (2009) 1.62
Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One (2013) 1.37
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther (2011) 1.29
Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol (2009) 1.29
Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 1.21
Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol (2013) 1.08
Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol (2013) 1.07
Idiopathic membranous nephropathy in children. Pediatr Nephrol (2006) 1.05
Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol (2009) 1.03
Controversies in the treatment of idiopathic membranous nephropathy. Nat Rev Nephrol (2009) 1.02
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol (2016) 1.02
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol (2014) 0.94
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis (2014) 0.92
Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int (2015) 0.90
Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. J Am Soc Nephrol (2015) 0.89
Patient age and the prognosis of idiopathic membranous nephropathy. PLoS One (2014) 0.86
Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol (2009) 0.86
Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med (2012) 0.85
Membranous glomerulonephritis: treatment response and outcome in children. Pediatr Nephrol (2008) 0.84
Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant (2010) 0.83
Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatr Nephrol (2008) 0.81
The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. Clin Kidney J (2014) 0.80
Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol (2017) 0.80
Smoking is a risk factor for the progression of idiopathic membranous nephropathy. PLoS One (2014) 0.79
Stepwise treatment using corticosteroids alone and in combination with cyclosporine in korean patients with idiopathic membranous nephropathy. Yonsei Med J (2013) 0.79
Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl (2011) (2012) 0.78
Membranous Nephropathy: Quantifying Remission Duration on Outcome. J Am Soc Nephrol (2016) 0.78
Membranous nephropathy: Treatment outline and risk stratification. Avicenna J Med (2012) 0.77
Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Clin Exp Nephrol (2013) 0.77
Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. Clin Exp Nephrol (2008) 0.77
Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab. KI Rep (2016) 0.77
Effect of steroid and cyclosporine in membranous nephropathy that is resistant to steroid and/or cytotoxic treatment. Int J Clin Exp Med (2014) 0.76
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. BMC Nephrol (2017) 0.75
Depletion of B lymphocytes in idiopathic membranous glomerulopathy: results from patients with extended follow-up. Nephron Extra (2013) 0.75
Management of Membranous Nephropathy in Western Countries. Kidney Dis (Basel) (2015) 0.75
Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2014) 0.75
Treatment with rituximab in idiopathic membranous nephropathy. Clin Kidney J (2016) 0.75
Immunosuppressive Medications. Clin J Am Soc Nephrol (2015) 0.75
Membranous nephropathy-one morphologic pattern with different diseases. Pflugers Arch (2017) 0.75
Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. PLoS One (2017) 0.75
Lupus-like membranous nephropathy: Is it lupus or not? Clin Exp Nephrol (2014) 0.75
Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis. Intern Med (2017) 0.75
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med (1992) 4.33
The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. N Engl J Med (1999) 4.03
Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 3.57
Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis (1990) 2.91
Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker. Kidney Int (2007) 2.84
The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54
Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol (2001) 2.54
Pathologic findings in mesangiopathic glomerulonephritis in Navajo Indians. Arch Pathol Lab Med (1989) 2.48
Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. Kidney Int (2006) 2.41
An epidemic of renal failure among Australian Aboriginals. Med J Aust (1998) 2.38
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int (1996) 2.21
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int (2006) 2.18
Eosinophilia in maintenance hemodialysis patients. J Dial (1979) 2.16
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol (2001) 2.10
Beta-adrenoceptor blocking properties and cardioselectivity of M & B 17,803A. Br J Pharmacol (1973) 2.09
Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol (1999) 1.95
The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med (1977) 1.93
OPTN policy regarding prioritization of patients with hepatopulmonary syndrome: does it provide equitable organ allocation? Am J Transplant (2008) 1.88
Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life. Med J Aust (2001) 1.85
Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis (1978) 1.83
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int (1999) 1.82
Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest (1966) 1.81
The living donor in kidney transplantation. Ann Intern Med (1987) 1.81
The nephrotoxicity of antimicrobial agents (second of three parts). N Engl J Med (1977) 1.79
Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA (1976) 1.77
Gentamicin in 1978. Ann Intern Med (1978) 1.73
Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (1991) 1.66
C3b inactivator of man. 3. Further purification and production of antibody to C3b INA. J Immunol (1972) 1.64
HIV infection and the kidney. J Am Soc Nephrol (1997) 1.62
Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) (1978) 1.57
The role of monocytes in serum sickness nephritis. J Exp Med (1979) 1.55
Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest (1984) 1.46
Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group. Control Clin Trials (1991) 1.45
Renoprotective therapy: how good can it get? Kidney Int (2000) 1.39
Therapy of membranous nephropathy: what to do after the after (meta) analyses. J Am Soc Nephrol (1995) 1.39
A comparison of the actions of some drugs on decerebrate rigidity, muscle spindle activity and alpha-adrenoceptors. Br J Pharmacol (1974) 1.33
Update on the treatment of lupus nephritis. Kidney Int (2006) 1.33
Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis (1996) 1.31
The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am (1984) 1.31
The nephrotoxicity of antimicrobial agents (third of three parts). N Engl J Med (1977) 1.30
The effect of transplant center volume on cardiac transplant outcome. A report of the United Network for Organ Sharing Scientific Registry. JAMA (1994) 1.28
Renal pathology of human immunodeficiency virus infection. Semin Nephrol (1998) 1.28
Short- and long-term outcomes with the use of kidneys and livers donated after cardiac death. Am J Transplant (2006) 1.27
Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol (1994) 1.27
CR1 and CR1-like: the primate immune adherence receptors. Immunol Rev (2001) 1.27
Bronchodilator activity of an aerosol of prostaglandin E1 in experimental animals. Nature (1969) 1.27
Center-specific graft and patient survival rates: 1997 United Network for Organ Sharing (UNOS) report. JAMA (1998) 1.27
The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med (1994) 1.26
Studies on cytophilic antibodies. V. Alloantibodies cytophilic for mouse macrophages. Aust J Exp Biol Med Sci (1969) 1.25
Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr (2004) 1.21
The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus (2010) 1.21
Epidemic renal disease of unknown etiology in the Zuni Indians. Am J Kidney Dis (1987) 1.20
Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. Antimicrob Agents Chemother (1979) 1.19
Minimal change disease in systemic lupus erythematosus. Clin Nephrol (2002) 1.19
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int (2007) 1.18
Renal artery dissection causing renal infarction in otherwise healthy men. Am J Kidney Dis (1997) 1.17
Renal vein thrombosis, nephrotic syndrome, and systemic lupus erythematosus: an association in four cases. Ann Intern Med (1976) 1.16
Cost-effective care of end-stage renal disease: a billion dollar question. Ann Intern Med (1980) 1.15
The syndrome of multiple endocrine gland insufficiency. Am J Med (1976) 1.15
Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int (1986) 1.12
The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis (1995) 1.12
Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation (1989) 1.12
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
Failure of plasma exchange and immunosuppression to improve renal function in Goodpasture's syndrome. Clin Nephrol (1978) 1.10
A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors. Br J Pharmacol (1972) 1.10
5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol (2012) 1.10
The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med (1985) 1.09
Revascularization for preservation of renal function in patients with atherosclerotic renovascular disease. J Urol (1983) 1.08
A comparison of the effects of chlorpromazine and some related phenothiazines in reducing the rigidity of the decerebrate cat and in some other central actions. Br J Pharmacol Chemother (1967) 1.08
The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis (1993) 1.08
The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int (1987) 1.07
Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med (1989) 1.07
The effects of dimethothiazine on muscle spindle activity in the decerebrate cat. Br J Pharmacol (1970) 1.06
Mezlocillin pharmacokinetics in renal impairment. Clin Pharmacol Ther (1980) 1.05
Noradrenergic receptors and the control of fusimotor activity. J Physiol (1972) 1.05
Some hemodynamic determinants of immune complex trapping by the kidney. Kidney Int (1978) 1.05
Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin Immunol Immunopathol (1987) 1.04
Acute reversible proteinuria induced by infusion of the polycation hexadimethrine. Kidney Int (1981) 1.04
Body size measurements as predictors of type 2 diabetes in Aboriginal people. Int J Obes Relat Metab Disord (2004) 1.03
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Delayed graft function: state of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant (2001) 1.02
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis (1999) 1.02
Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron (1986) 1.02
Glomerular size and glomerulosclerosis in Australian aborigines. Am J Kidney Dis (2000) 1.01
Trends in surgical revascularization for renal artery disease. Ten years' experience. JAMA (1987) 1.01